General Atomics
SAN DIEGO, CA / ACCESSWIRE / April 24, 2024 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has been selected to build production representative flight test articles of the Collaborative Combat Aircraft (CCA) for the U.S. Air Force Life Cycle Management Center's (AFLCMC) Advanced Aircraft Division. This option contract award by the Advanced Aircraft Division exercises the critical design, build, and flight test on the existing CCA contract with GA-ASI following an initial six-month phase that culminated in a successful CCA preliminary design review (PDR) earlier this year.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.The CCA program aims to be a force multiplier, developing a low-cost, modular, unmanned aircraft equipped with advanced sensors or weapons and operating in collaborative teams with the next generation of manned combat aircraft.
In February 2024, GA-ASI successfully conducted the maiden flight of the XQ-67A CCA prototype aircraft validating the "genus/species" concept pioneered by the Air Force Research Laboratory (AFRL) as part of the Low-Cost Attritable Aircraft Platform Sharing (LCAAPS) program. This program focused on building several aircraft variants from a common core chassis. Since then, this prototype for CCA has successfully completed two additional test flights, laying the groundwork for a successful production and flight test program. GA-ASI's CCA production representative design is based upon the XQ-67A Off-Board Sensing Station developed by GA-ASI for the AFRL.
"The CCA program redefines the future of aviation and will shape the USAF acquisition model to deliver affordable combat mass to the warfighter at the speed of relevancy," said Mike Atwood, Vice President of Advanced Programs for GA-ASI.
"Throughout our 30-year history, GA-ASI has been at the forefront of rapidly advancing unmanned aircraft systems that support our warfighters," said GA-ASI President David R. Alexander. "The USAF is moving forward with GA-ASI due to our focused commitment to unmanned air-to-air combat operations and unmatched UAS experience, ensuring the production of the CCA aircraft at scale to deliver affordable combat mass for the warfighter."
To complement the CCA contract, GA-ASI will continue to conduct a series of autonomy and mission system tests on the MQ-20 Avenger® UAS and XQ-67A to accelerate the readiness of operational autonomy. These live flight tests will continue to demonstrate the readiness of the full mission capability to support the emerging U.S. Air Force Autonomous Collaborative Platforms (ACP).
About GA-ASI
General Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable RPA systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent situational awareness. The company also produces a variety of sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas.
For more information, visit www.ga-asi.com.
Avenger, Lynx, Predator, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.
Contact Information:
GA-ASI Media Relations
asi-mediarelations@ga-asi.com
+1 (858) 524-8101
SOURCE: General Atomics Aeronautical Systems, Inc.
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
